20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Gainers

• Miragen Therapeutics, Inc. MGEN shares rose 31.96% to $1.24 during Wednesday's pre-market session.

• Venus Concept, Inc. VERO stock increased by 19.75% to $4.85. According to the most recent rating by Oppenheimer, on Mar 31, the current rating is at Perform.

• Fulgent Genetics, Inc. FLGT stock increased by 15.27% to $19.02. The most recent rating by BTIG, on May 29, is at Buy, with a price target of $20.

• FSD Pharma, Inc. HUGE shares moved upwards by 10.60% to $4.80.

• electroCore, Inc. ECOR stock increased by 10.59% to $1.07. The most recent rating by H.C. Wainwright, on Mar 24, is at Buy, with a price target of $2.

• CTI BioPharma, Inc. CTIC shares rose 9.65% to $1.25.

• Millendo Therapeutics, Inc. MLND stock rose 8.82% to $2.59. The most recent rating by Citigroup, on May 29, is at Buy, with a price target of $6.

• ContraFect, Inc. CFRX stock increased by 7.51% to $6.73. The most recent rating by Cantor Fitzgerald, on Jun 9, is at Overweight, with a price target of $15.

• Heat Biologics, Inc. HTBX stock increased by 7.44% to $0.82.

• Moleculin Biotech, Inc. MBRX shares rose 7.34% to $1.17.

Losers

• Chembio Diagnostics, Inc. CEMI shares fell 56.70% to $4.30 during Wednesday's pre-market session. The most recent rating by Canaccord Genuity, on Jun 17, is at Hold, with a price target of $7.

• BioCardia, Inc. BCDA stock declined 18.97% to $2.35.

• AVEO Pharmaceuticals, Inc. AVEO shares decreased by 13.60% to $5.40. The most recent rating by HC Wainwright & Co., on May 1, is at Buy, with a price target of $10.

• Edesa Biotech, Inc. EDSA stock declined 9.37% to $6.

• Brickell Biotech, Inc. BBI shares declined 8.82% to $1.55.

• Xenetic Biosciences, Inc. XBIO stock declined 6.72% to $1.11.

• Aphria, Inc. APHA shares fell 5.80% to $4.22.

• Seneca Biopharma, Inc. SNCA stock fell 5.17% to $0.81.

• China SXT Pharmaceuticals, Inc. SXTC stock fell 5.06% to $0.45.

• Radius Health, Inc. RDUS shares fell 5.01% to $12.51. The most recent rating by Morgan Stanley, on May 13, is at Equal-Weight, with a price target of $20.